Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate

Department of Pathology, Children's Medical Center, Dallas, TX, USA.
Tumor Biology (Impact Factor: 3.61). 11/2010; 32(2):325-33. DOI: 10.1007/s13277-010-0125-6
Source: PubMed


Elevated levels of D: -2-hydroxyglutarate (D: -2-HG) occur in gliomas and myeloid leukemias associated with mutations of IDH1 and IDH2. L: -2-Hydroxyglutaric aciduria, an inherited metabolic disorder, predisposes to brain tumors. Therefore, we asked whether sporadic cancers, without IDH1 or IDH2 hot-spot mutations, show elevated 2-hydroxyglutarate levels. We retrieved 15 pairs of frozen papillary thyroid carcinoma (PTC) and adjacent non-neoplastic thyroid, and 14 pairs of hyperplastic nodule (HN) and adjacent non-hyperplastic thyroid. In all lesions, exon 4 sequencing confirmed the absence of known mutations of IDH1 and IDH2. We measured 2-hydroxyglutarate by liquid chromatography-tandem mass spectrometry. Compared to normal thyroid, PTCs had significantly higher D: -2-HG and L: -2-hydroxyglutarate (L: -2-HG) levels, and compared to HNs, PTCs had significantly higher D: -2-HG levels. D: -2-HG/L: -2-HG levels were not significantly different between HNs and normal thyroid. Further studies should clarify if elevated 2-hydroxyglutarate in PTC may be useful as cancer biomarker and evaluate the role of 2-hydroxyglutarate in cancer biology.

Download full-text


Available from: Richard L. Boriack, Jun 19, 2015
  • Source
    • "Quantitation of ( L ) - 2HG and ( D ) - 2HG Measurement of D - 2HG and L - 2HG was performed as described previously ( Rakheja et al . , 2011a , 2011b ) . Briefly , the metabolite extracts were derivatiza - tion with ( + ) - Di - O - acetyl - L - tartaric anhydride and injected for chromato - graphic separation on an Agilent Hypersil ODS 4 . 0 3 250 mm , 5 mm column followed by detection and measurement using an API 3000 triple - quadrupole mass spectrometer equipped with an E"
    [Show abstract] [Hide abstract]
    ABSTRACT: Mammalian cells generate citrate by decarboxylating pyruvate in the mitochondria to supply the tricarboxylic acid (TCA) cycle. In contrast, hypoxia and other impairments of mitochondrial function induce an alternative pathway that produces citrate by reductively carboxylating α-ketoglutarate (AKG) via NADPH-dependent isocitrate dehydrogenase (IDH). It is unknown how cells generate reducing equivalents necessary to supply reductive carboxylation in the setting of mitochondrial impairment. Here, we identified shared metabolic features in cells using reductive carboxylation. Paradoxically, reductive carboxylation was accompanied by concomitant AKG oxidation in the TCA cycle. Inhibiting AKG oxidation decreased reducing equivalent availability and suppressed reductive carboxylation. Interrupting transfer of reducing equivalents from NADH to NADPH by nicotinamide nucleotide transhydrogenase increased NADH abundance and decreased NADPH abundance while suppressing reductive carboxylation. The data demonstrate that reductive carboxylation requires bidirectional AKG metabolism along oxidative and reductive pathways, with the oxidative pathway producing reducing equivalents used to operate IDH in reverse.
    Full-text · Article · May 2014 · Cell Reports
  • Source
    • "Although the source of 2-HG is not fully understood, experimental evidences indicate that IDH1 and IDH2 have a role in the production of d-2-HG (Matsunaga et al., 2012). d-2-HG and its enantiomer l-2-HG are linked to the Krebs cycle (Raimundo et al., 2011) and are found to be elevated in certain types of cancer (Dang et al., 2009; Rakheja et al., 2011) and in different variants of the neurometabolic 2-hydroxyglutaric aciduria. In relation to the latter defect, a recent study from Nota et al. (2013) reported 12 recessive mutations (Ser193Trp, Arg282Gly, Arg282Cys, Gly167Arg, Pro45Leu, Glu144Gln, Met202Thr, Tyr297Cys, Tyr256*, Ala9Profs*82, A274Ilefs*24, and Arg- 173Glyfs*2) found in the CIC gene of three individuals and their families that cause combined d-2-and l-2-hydroxyglu- taric aciduria. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Citrate is an important substrate in cellular energy metabolism. It is produced in mitochondria and used in the Krebs cycle or released into cytoplasm through a specific mitochondrial carrier, CIC. In the cytosol citrate and its derivatives, acetyl-CoA and oxaloacetate, are used in normal and pathological processes. Beyond the classical role as metabolic regulator, recent studies have highlighted that citrate is involved in inflammation, cancer, insulin secretion, histone acetylation, neurological disorders and NAFLD (Non-alcoholic fatty liver disease). Monitoring changes in the citrate levels could therefore potentially be used as diagnostic tool. This review highlights these new aspects of citrate functions.
    Full-text · Article · Jan 2014 · Biological Chemistry
  • Source
    • "Isocitrate dehydrogenase mutations can be detected by a number of methods including polymerase chain reaction (PCR)-based assays (Felsberg et al., 2010; Meyer et al., 2010; Patel et al., 2011b; Rakheja et al., 2011a), expression of IDH1 mutant protein in tumor tissue as detected by mutation specific antibody using immunohistochemistry (Andrulis et al., 2010; Capper et al., 2010), and indirectly by detecting the putative oncometabolite, d-2HG, by mass-spectrometry in vitro or by magnetic resonance spectroscopy in vivo (Gross et al., 2010; Rakheja et al., 2011b; Choi et al., 2012; Sahm et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 20% of unselected cases and 30% cytogenetically diploid cases of acute myeloid leukemia (AML) and 80% of grade II-III gliomas and secondary glioblastomas carry mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. IDH1/2 mutations prevent oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) and modulate the function of IDH (neomorphic activity) thereby facilitating reduction of α-KG to D-2-hydroxyglutarate (D-2HG), a putative oncometabolite. D-2HG is thought to act as a competitive inhibitor of α-KG-dependent dioxygenases that include prolyl hydroxylases and chromatin-modifying enzymes. The end result is a global increase of cellular DNA hypermethylation and alterations of the cellular epigenetic state, which has been proposed to play a role in the development of a variety of tumors. In this review, we provide an update on potential molecular mechanisms linking IDH1/2 mutations and the resulting oncometabolite, D-2HG, with malignant transformation. In addition, in patients with AML and glioma we focus on the associations between IDH1/2 mutations and clinical, morphologic, cytogenetic, and molecular characteristics.
    Full-text · Article · Jul 2013 · Frontiers in Oncology
Show more